West Virginia University Logo

COVID-19 Funding Opportunities

Special Extramural COVID-19 Funding Opportunities

NIH Opportunities:

For Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding and the current Funding Opportunities Specific to COVID-19, please visit https://grants.nih.gov/policy/natural-disasters/corona-virus.htm.

NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional)
(RFA-RM-20-020) Office of Strategic Coordination (Common Fund)

This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Transformative Research Awards (through this FOA) or Early Independence Awards (through RFA-RM-20-021) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally.

Application Receipt Date(s): September 30, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

NIH Directors Emergency Early Independence Awards (DP5 Clinical Trial Optional)
(RFA-RM-20-021) Office of Strategic Coordination (Common Fund)

This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Early Independence Award applications must be submitted in response to RFA-RM-20-014. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Early Independence Awards (through this FOA) or Transformative Research Awards (through RFA-RM-20-020) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally.

Application Receipt Date(s): September 4, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

NOT-AI-20-051, Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

National Institute of Allergy and Infectious Diseases

NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in select scientific areas using the following funding mechanisms.

This notice applies to due dates on or after June 16, 2020 and subsequent receipt dates through September 8, 2021.  Please see FOA for specific due dates for submission of proposals.

Related Announcements to Apply Under:

  • PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  • PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  • PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

Notice of Special Interest (NOSI): Availability of Urgent Award for Competitive Revisions to IDeA-CTR Awards to Address the Need for Documenting 2019 Novel Coronavirus Disease (COVID-19)-Related Patient Outcomes
(NOT-GM-20-033)  National Institute of General Medical Sciences

PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

NIGMS will accept applications for Competitive Revisions to active IDeA-CTR U54 awards to rapidly provide supplementary funds to create a registry of COVID-19 patients across IDeA states that includes a comprehensive set of deidentified clinical data elements.

First available due date for this opportunity is June 18, 2020.

Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)

(RFA-HS-20-003) Agency for Healthcare Research and Quality
This Funding Opportunity Announcement (FOA) invites R01 grant applications for funding to support novel, high-impact studies evaluating the responsiveness of healthcare delivery systems, healthcare professionals, and the overall U.S. healthcare system to the COVID-19 pandemic.

Application Receipt Date(s): June 15, 2020

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR

(NOT-DE-20-022)

National Institute of Dental and Craniofacial Research and Office of Research on Women's Health

The following FOA’s apply to this funding opportunity:

PA-18-591, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)” and

PA-18-935, “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)”

The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices. These topics include prevention of SARS-COV-2 transmission and improvements in the detection and diagnosis of COVID-19; as well as acquisition of a more robust understanding of SARS-CoV-2 pathogenesis. Application due dates: June 1, 2020, and November 2, 2020, by 5:00 PM.

Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) - The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards, (except R13s, T32s, F32s), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. Application due: May 31, 2020.  https://grants.nih.gov/grants/guide/pa-files/PA-20-070.html

Agency for Health Care Research and Quality Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) - The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards that were funded under the PCOR FOAs that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. The proposed projects must support dissemination of comparative clinical effectiveness research findings or the training of researchers in the methods used to conduct such research. Funding will be available in Fiscal Year 2020.  Application due: May 31, 2020.  https://grants.nih.gov/grants/guide/pa-files/PA-20-072.html

Notice of Special Interest (NOSI):? Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR
(NOT-DE-20-022)
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health

The following FOA’s apply to this funding opportunity:

PA-18-591, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)” and

PA-18-935, “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)”

The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices. These topics include prevention of SARS-COV-2 transmission and improvements in the detection and diagnosis of COVID-19; as well as acquisition of a more robust understanding of SARS-CoV-2 pathogenesis.  Application due dates: June 1, 2020, and November 2, 2020, by 5:00 PM.

NIH POCTRN Rapid Acceleration of Diagnostics call for proposals

https://www.poctrn.org/radx.

Fast-Track Program for COVID-19 Test Development and Distribution

Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing

NIH POCTRN is now accepting proposals for support on a rolling basis until further notice.

Through this opportunity, the NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution. 

Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA

NOT-AA-20-011

Participating Organizations: (NIAAA)

Release Date: April 16, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)

NOT-LM-20-010

Participating Organizations: (NLM)

Release Date: April 16, 2020

Notice of National Institute of Dental and Craniofacial Research (NIDCR) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

NOT-DE-20-020

Participating Organizations: (NIDCR), (NHGRI), (NIA), (NIAAA), (NIAID), (NIBIB), (NICHD), (NIDCR), (NIDDK), (NIDA), (NIEHS), (NIMH), (NIMHD), (NCI)

Release Date: April 14, 2020

Notice of Common Funds Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

NOT-RM-20-016

Participating Organizations: (Common Fund), (NHGRI), (NIAID), (NIBIB), (NICHD), (NIDDK), (NIEHS), (NIGMS), (NIMHD), (NCCIH), (NCI)

Release Date: April 14, 2020

Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2 NOT-NS-20-046

Participating Organizations: (NINDS)

Release Date: April 14, 2020

Notice of Participation of NIAAA in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional"

NOT-AA-20-007

Participating Organizations: (NIAAA)

Release Date: April 13, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

NOT-OD-20-097

Participating Organizations: (OBSSR), (NHLBI), (NIA), (NIAAA), (NIDDK), (NIEHS), (NCCIH), (NCI), (NICHD), (ODP), (ORWH)

Release Date: April 13, 2020

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

NOT-ES-20-020

Participating Organizations: (NIEHS)

Release Date: April 10, 2020

Notice of Early Expiration of NOT-ES-20-015, "Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

NOT-ES-20-019

Participating Organizations: (NIEHS)

Release Date: April 10, 2020

NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)

NOT-ES-20-017

Participating Organizations: (NIEHS)

Release Date: April 10, 2020

Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)"

NOT-ES-20-016

Participating Organizations: (NIEHS)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

NOT-EB-20-008

Participating Organizations: (NIBIB)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

NOT-EB-20-007

Participating Organizations: (NIBIB)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

NOT-EB-20-006

Participating Organizations: (NIBIB)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19

NOT-GM-20-027

Participating Organizations: (NIGMS)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

NOT-AT-20-011

Participating Organizations: (NCI), (NCCIH), (NIA), (NIAAA)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-CA-20-042

Participating Organizations: (NCCIH), (NIA), (NIAAA), (NCI)

Release Date: April 10, 2020

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission

NOT-DK-20-020

Participating Organizations: (NIDDK)

Release Date: April 9, 2020

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities

NOT-MD-20-019

Participating Organizations: (NIMHD)

Release Date: April 9, 2020

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus

NOT-TR-20-017

Participating Organizations: (NCATS)

Release Date: April 9, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus

NOT-MH-20-047

Participating Organizations: (NIMH), (NIA), (NIAAA), (NIMHD), (ODP)

Release Date: April 9, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

NOT-TR-20-016

Participating Organizations: (NCATS)

Release Date: April 9, 2020

Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-CA-20-043

Participating Organizations: (NCI)

Release Date: April 9, 2020

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

NOT-ES-20-015

Participating Organizations: (NIEHS)

Release Date: April 9, 2020

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK

NOT-DK-20-018

Participating Organizations: (NIDDK)

Release Date: April 9, 2020

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)

NOT-DC-20-004

Participating Organizations: (NIDCD)

Release Date: April 9, 2020

NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-HL-20-759

Participating Organizations: (NHLBI)

Release Date: April 8, 2020

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-AG-20-022

Participating Organizations: (NIA), (NIMH)

Release Date: April 2, 2020

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

NOT-HG-20-030

Participating Organizations: (NHGRI)

Release Date: March 31, 2020

Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)

NOT-ES-20-014

Participating Organizations: (NIEHS)

Release Date: March 27, 2020

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

NOT-TR-20-012

Participating Organizations: (NCATS)

Release Date: March 27, 2020

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome

NOT-AI-20-034

Participating Organizations: (NIAID)

Release Date: March 25, 2020

Notice of Early Expiration of “Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019

NOT-AI-20-040

Participating Organizations: (NIAID)

Release Date: March 25, 2020

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

NOT-GM-20-025

Participating Organizations: (NIGMS)

Release Date: March 25, 2020

Notice of Special Interest (NOSI) Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need

NOT-TR-20-011

Participating Organizations: (NCATS)

Release Date: March 24, 2020

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

NOT-DA-20-047

Participating Organizations: (NIDA)

Release Date: March 19, 2020

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NOT-HL-20-757

Participating Organizations: (NHLBI)

Release Date: March 17, 2020

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)

NOT-AI-20-030

Participating Organizations: (NIAID), (NIGMS)

Release Date: February 6, 2020

Department of Defense Opportunities:

Newton Award for Transformative Ideas during the COVID-19 Pandemic

Funding Opportunity Number: BRO-20-NEWTON

Deadline: 5/15/2020

This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. Proposals should aim to produce novel conceptual frameworks or theory-based approaches that present disruptive ways of thinking about fundamental scientific problems that have evaded resolution, propose new, paradigm-shifting scientific directions, and/or address fundamental and important questions that are argued to be undervalued by the scientific community. Approaches can include analytical reasoning, calculations, simulations, and thought experiments. While data collection and production are therefore allowed, all supporting data should be generated without the use of laboratory-based experimentation or instrumentation.

CDMRP PRMRP Clinical Trial Award for Emerging Viral Diseases and Respiratory Health

https://www.grants.gov/web/grants/view-opportunity.html?oppId=326173

Deadlines: Pre-Application: 6/08/2020; Full application: 6/22/2020

The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact in one or more of the Focus Areas published in this funding opportunity for the FY20 PRMRP Congressionally specified Topic Areas of Emerging Viral Diseases and Respiratory Health. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. All applications for this Program Announcement must specifically address at least one of the following Focus Areas and must be of clear scientific merit and direct relevance to military health: Emerging Viral Diseases or Respiratory Health.

CDMRP PRMRP Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health

https://www.grants.gov/web/grants/view-opportunity.html?oppId=326174

Deadlines: Pre-Application: 5/28/2020; Full application: 6/12/2020

The PRMRP Investigator-Initiated Research Award is intended to support studies that will make an important contribution toward research and/or patient care in one or more Focus Areas published in this Funding Opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature. All applications for this Program Announcement must specifically address at least one of the following Focus Areas and must be of clear scientific merit and direct relevance to military health: Emerging Viral Diseases or Respiratory Health.

CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health

https://www.grants.gov/web/grants/view-opportunity.html?oppId=326175

Deadlines: Pre-Application: 5/28/2020; Full application: 6/12/2020

The PRMRP Technology/Therapeutic Development Award is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications in one or more Focus Areas published in this funding opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries. All applications for this Program Announcement must specifically address at least one of the following Focus Areas and must be of clear scientific merit and direct relevance to military health.

DOD Prototype Development to Combat COVID-19

The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a potential Request for Project Proposals (RPP) focused on the development of prototypes aimed to combat the coronavirus (COVID-19). In light of the magnitude and potential threat that the coronavirus (COVID-19) poses to the military’s health and readiness, the government seeks to rapidly accelerate the inquiry, testing, and fielding of new 21st century capabilities, employing novel technologies and approaches to the detection of exposure, prevention, containment and treatment of COVID-19 and future emerging threats. MTEC believes that an emphasis will be placed on technologies that can be deployed as soon as possible but no later than 31 December 2020. In support of this, MTEC has identified the following potential areas of interest: Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19. Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans for the prevention/treatment of COVID-19 are preferred.

Although there is no specific funding commitment by the U.S. Government at this time, MTEC believes that there may be tens of millions of dollars available for combating COVID-19 programs with a likelihood of follow-on funding. The upcoming RPP(s) will be posted to the MTEC website and a notice will be posted here to notify interested parties. Contingent upon approval from the Government, the upcoming RPP(s) is expected to be released within the next few weeks and will have an extremely short preparation period (approximately 14 days).

Application Deadline: TBA

Medical CBRN Defense Consortium Opportunities:

Medical CBRN Defense Consortium (MCDC) Request for Information (RFI) – CoV Pandemic Response

https://www.medcbrn.org/cov-pandemic-response/

Deadline: 5/31/2020

The purpose of this special notice is to obtain information via White Papers from both MCDC members and other interested industry/academia partners in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.). The Government is requesting White Papers with a focus on the following areas:

  • Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, and achieving Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) within the next one to four (1-4) months.
  • Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening. Any technology that can enhance the understanding of disease progression in COVID-19 infected patients is also of interest, including physiologic monitoring and other vital signs indicators, portable technology that enhances patient care in non-hospital settings, and technology that improves sample collection.
  • Information systems and technology the Government can use in a handheld Point-of-Care device to collect, screen, collate, report, and monitor disease infection and pandemic spread on a micro and macro level.
  • Therapeutics: Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next three (3) months for this ongoing SARS-CoV-2 pandemic. Antibody technologies, accelerating the discovery, development, manufacturing, and prediction of success for these technologies, can also be considered.
  • Prophylactics: Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered.
  • Clinical Trials: Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered. MCDC is requesting proposals regarding rapidly deployable (1-6 months) products and technologies to combat the current pandemic. Longer-term solutions are not requested in this RFI.

NSF Opportunities:

RAPID: Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, they invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200,000 and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to this e-mail address.

Application Deadline: RAPIDs on rolling basis, others vary by directorate

Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)

This Dear Colleague Letter (DCL) complements a separate National Science Foundation (NSF) DCL (NSF 20-052) that referred to the emergence of the coronavirus disease 2019 (COVID-19) and expressed NSF's interest in accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to better understand how to model and understand the spread of COVID-19; to inform and educate about the science of virus transmission and prevention; and to encourage the development of processes and actions to address this global challenge.

CDC Opportunities:

https://www.cdc.gov/grants/public-health-emergencies/covid-19/index.html

CDC Crisis Response Mechanism for Funding State, Local, Territorial and Tribal (SLTT) Public Health Departments During a Public Health Response (TP-18-1802)

CDC has awarded nearly $730 million in funding under Components A and B of the cooperative agreement to the 65 eligible jurisdictions that are on the approved but unfunded (ABU) list for CDC-RFA-TP18-1802 to provide resources to prevent, prepare for, and respond to COVID-19. This funding is intended for state, local, territorial, and tribal health departments to carry out surveillance, epidemiology, laboratory capacity, infection control, mitigation, communications, and other preparedness and response activities.

Epidemiology and Laboratory Capacity for the Prevention and Control of Emerging Infectious Diseases (ELC) (CK19-1904 2019)

CDC 24/7 Response and Support for COVID-19 Activities

CDC has awarded nearly $730 million in funding under Components A and B of the cooperative agreement to the 65 eligible jurisdictions that are on the approved but unfunded (ABU) list for CDC-RFA-TP18-1802 to provide resources to prevent, prepare for, and respond to COVID-19. This funding is intended for state, local, territorial, and tribal health departments to carry out surveillance, epidemiology, laboratory capacity, infection control, mitigation, communications, and other preparedness and response activities.

PCORI Funding Opportunities:

Eugene Washington PCORI Engagement Award Special Cycle: Supporting Engagement in and Dissemination of PCOR/CER in the Context of COVID-19

Deadline: 5/22/2020

This Eugene Washington PCORI Engagement Award Special Cycle Funding Announcement—Supporting Engagement in and Dissemination of PCOR/CER in the Context of COVID-19—aims to support projects that help communities increase their capacity to participate across all phases of the PCOR/CER process while responding to contextual changes as a result of the COVID-19 pandemic. This is an opportunity to explore virtual/distanced methods of engagement and generate new questions and evidence needs across stakeholder groups.

COVID-19 Targeted PFA

Deadline: 5/26/2020

In order to respond to the COVID-19 pandemic, PCORI intends to publish a new research funding announcement to support innovative, high-impact studies that fit clearly within our core mission of patient-engaged and patient-centered comparative clinical effectiveness research. The objectives of this announcement are to (1) strengthen the understanding of different approaches to mitigate the impact of COVID-19 on individuals, communities, healthcare providers, and healthcare systems; and (2) provide evidence to inform clinical and public health responses, decision making, and planning. PCORI will encourage the use of diverse methods, including interventional studies and the use of natural experiments, to conduct research on an accelerated timeline with the ability to complete primary outcomes collection and provide actionable findings in no longer than 12 months.

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects

Deadline: applications currently accepted on a rolling basis

PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards

Deadline: applications currently accepted on a rolling basis

PCORI is currently seeking Project Lead-initiated proposals to address the COVID-19 public health crisis through enhancements to currently funded PCORI Engagement Awards. Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement.

American Lung Association Opportunities:

American Lung Association COVID-19 and Emerging Respiratory Viruses Research Award

COVID-19 and Emerging Respiratory Viruses Research Award

Deadline: 5/30/2020

There is an urgent need to better understand the pathobiology and clinical implications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection that leads to the morbidity and mortality seen with COVID-19, as well as increase knowledge about the potential emerging threat of other novel respiratory viruses. We are looking for proposals to advance research against emerging respiratory pathogens like SARS-CoV-2. All research must directly be related to COVID-19 or other viral respiratory threats that may arise in the future.

ENVIRONMENTAL PROTECTION AGENCY (EPA) Opportunities:

Removal Emergency Response Program

https://www.epa.gov/sites/production/files/2020-04/documents/19-08.pdf

Deadline: 6/10/2020

This notice announces the availability of funds and solicits applications from eligible entities to promote the participation of individual State and territorial programs in research activities with the mission of advocating for and supporting State emergency response readiness and removal program planning and preparedness.

Solve at MIT:

https://solve.mit.edu/challenges/health-security-pandemics

Deadline: 6/18/2020

In the near term, we need improved solutions for prevention, accurate detection, and rapid response. MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers.

Amazon Web Services Opportunities:

AWS Diagnostic Development Initiative (DDI)

Deadline: 6/30/2020

The AWS Diagnostic Development Initiative (DDI) provides support for innovation in rapid and accurate patient testing for 2019 novel coronavirus (COVID-19), and other diagnostic solutions to mitigate future outbreaks. Although vaccine and treatment development research is generally funded by private foundations and government agencies, fast and reliable diagnostic techniques are slow to be developed. Accurate testing and diagnosis at point-of-care or regional locations for patients with COVID-19 is critical to early intervention and treatment. AWS is offering technical support and providing AWS promotional credits to support the use of AWS services to advance diagnostic research for selected institutions and companies.

Pfizer Funding Opportunities:

COVID-19: Continuity in Care for Patients with Metastatic Breast Cancer Grant Support Program

Deadline: 5/21/2020

Funds are intended to be used to for initiatives that support patient adherence to treatment and reduce risk of patient exposure to COVID-19 such as home health services that allow licensed nurses to visit patients with metastatic breast cancer for potential blood draws and/or other monitoring the patient may require. The funds can be used for supplemental salary support, transportation costs, and other related items (not otherwise reimbursable by payors). Our goal is that the process of patient care delivery during the COVID-19 pandemic will be improved with this additional funding support. This RFP is aligned with a recent recommendation from the National Comprehensive Cancer Network (NCCN) Best Practices Committee to transition outpatient care to at-home care whenever possible (e.g., pump disconnection, administration of growth factors, hormone therapy). Ref. JNCCN─Journal of the National Comprehensive Cancer Network Safety During the COVID-19 Pandemic

COVID-19 Competitive Grant Program

Deadline: 5/22/2020

Through this RFP, it is our intent to support educational programs for healthcare providers focused on the recognition, diagnosis, treatment, and overall care management of patients with COVID-19.

InfoEd Global COVID-19/Coronavirus Resources for various funding Opportunities:

https://www.infoedglobal.com/COVID19/COVID-19

InfoEd Global is proud to be able to share this library of COVID-19 funding opportunities and resources with our colleagues in the research realm and the broader community at large.

USDA Funding Opportunities:

https://www.rd.usda.gov/sites/default/files/USDA_COVID-19_Fed_Rural_Resource_Guide.pdf

The COVID-19 Federal Rural Resource Guide is a helpful resource published by the U.S. Department of Agriculture unveiled by the USDA for rural communities looking for federal funding and partnership opportunities to help address COVID-19. This resource matrix organizes funding opportunities identified in the CARES Act and other federal resources that can help support rural America. Opportunities are categorized by customer and assistance type.